Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. 2cureX AB (“2cureX” or the “Company”) completed a directed issue of units during the third quarter of 2020. One (1) unit consisted of two (2) newly issued shares and one (1) warrant

Ortoma obtains CE certification for Spine Module

Ortoma has obtained CE certification for its spine module OTS Spine Plan now included in the platform Ortoma Treatment Solution (OTS). The spine module is a pre-operative planning solution for spine surgery. The OTS platform is a surgical system that is assisted by AI (Artificial Intelligence) for improved accuracy, efficiency and surgical outcome.CE certification for OTS Spine Plan is approved by the Notified Body and the CE-marked product is approved for use clinically in Europe. The OTS platform now includes CE marked products for hip replacement surgery and spine surgery.  In addition,

SOTKAMO SILVER AB: PRODUCTION UPDATE AND GUIDANCE 2021

Press release: Stockholm, April 23, 2021 08:45 CET Silver Mine has produced 3 million ounces silver since the production started in 2019. Silver production was 1,00 million ounces in 2019 and 1,58 million ounces in 2020. Silver production during the first quarter of 2021 reached 344 000 ounces and 3 million ounces milestone was achieved in mid-April. The production of the first three weeks of April was 97 000 ounces silver and the Company restates the production guidance for 2021 and expects to produce between 1,45 – 1,75 million ounces of silver in 2021. Stockholm April 23,

Interim report 2021, January 1 – March 31

January - March 2021 Net revenue for the period was SEK 87.7 million (83.7) EBITDA for the period was SEK 8.9 million (5.4) EBITA for the period was SEK 6.9 million (3.4) Profit/loss for the period was SEK 2.5 million (-2.5) Basic earnings per share for the period amounted to SEK 0.02 (-0.02) Orders received for the period totaled SEK 91.7 million (137.3) Operating cash flow for the period was SEK -1.3 million (8.7) CEO’s comments ADDvise entered the first quarter in a strong position, carrying momentum from the fourth quarter of 2020 into the new year with solid

OX2 acquires a 170 MW wind power project in Sweden from Stora Enso

OX2 and Stora Enso have agreed on the purchase of the Hälsingeskogen wind power project in the municipality of Ovanåker, Gävleborg County, Sweden.According to the agreement OX2 acquires 100 percent of the project rights from Stora Enso, which remains the landowner. The wind farm will include 37 wind turbines with a total possible capacity of 170 MW. The estimated annual electricity production amounts to approximately 380 GWh, which corresponds to the average electricity consumption for 72,000 households per year. “Wind power needs to be quadrupled if Sweden is to reach the national goal

C-RAD Web Presentation Interim Report Q1 2021 and AGM speech

Invitation to join the presentation of C-RAD’s first quarter 2021. CEO Tim Thurn will also give his Annual General Meeting speech at this event. The AGM is held on May 7 but without any presence from shareholders or other parties, as communicated previously in the call for the AGM. Date: Thursday May 7, 2021 / kl. 11:00 CET Venue: Online Presentation Topic: C-RAD Interim Report Q1 2021 / AGM speech Procedure: Please register online through the website:   https://us06web.zoom.us/webinar/register/WN_xs_0KzMGT7qEExqblSLzmw After the registration, you will receive a

EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its lead product candidate Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN), has been granted accelerated assessment procedure by the European Medicine Agency’s (EMA) Committee for Human Medicinal Products (CHMP).Accelerated assessment, which may be granted when the CHMP concludes that the product is of major public health interest and major therapeutic innovation pursuant to Article 14 (9) of Regulation (EC) No 726/

Sivers Semiconductors AB (publ) Annual Report 2020

Sivers Semiconductors AB today publishes the annual report for 2020.The full report can be found at Sivers Semiconductors home page: https://www.sivers-semiconductors.com/annual-reports/ For more information please contact:Anders Storm, CEOTel: +46 70 262 6390E-mail: anders.storm@sivers-semiconductors.comErik Penser Bank is appointed Sivers Semiconductors AB’s Certified Advisor at Nasdaq First North Growth Market.Tel: +46 8 463 80 00 E-mail: certifiedadviser@penser.se

Heliospectra (publ) Interim Report January-March 2021

(GOTHENBURG, Sweden, April 23, 2021)– Heliospectra AB (publ), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents Interim Report for January-March 2021.Full report is enclosed to this press release and is also uploaded at https://www.heliospectra.com/investor-relations/reports-documents-archive.   SUMMARY OF REPORT SALES AND FINANCIAL PERFORMANCE, JANUARY– MARCHNet sales amounted to KSEK 9,960 (15,200). The operating loss amounted to KSEK -7,302 (-9,058) KSEK, signifying a negative operating margin (neg). The loss

Interim Report January-March 2021 – Pricer AB (publ)

High order intake and net sales growth of 74 percentQ1 2021 ·Net sales amounted to SEK 392.9 M (225.9), an increase of 74 percent compared to the same period last year. ·Operating profit amounted to SEK 17.3 M (7.3), which corresponds to an operating margin of 4.4 percent (3.3). ·Order intake was SEK 443 M (371), an increase of 19 percent compared to the same period last year. ·Order backlog amounted to SEK 550 M (933), of which the majority is expected to be delivered in Q2 and Q3 2021. ·Profit for the period was SEK 17.7 M (14.8). ·Earnings per

Poster with 5-years’ follow-up data presented at the 3rd World Arthroplasty Congress available

Episurf Medical (Nasdaq: EPIS B) today announces that the poster presentation "Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years” by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, et al. which was presented at the 3rd World Arthroplasty Congress, is now available through Episurf Medical’s website. The poster presentation focuses on clinical results from the use of the Episealer® knee implant with a follow-up of up to 5 years (15 patients with 5 years’ results). The poster concludes that “This

Nanologica Interim Report Jan-Mar 2021

Summary of the period FINANCIAL OVERVIEW · Net revenue increased by 54 percent to TSEK 5,622 (3,654) · The operating profit and loss for the period was TSEK -6,768 (-6,032) · Profit and loss after tax for the period was TSEK -7,845 (-6,705) · Earnings per share for the period was SEK -0.28 (-0.40) · Cash and cash equivalents at the end of the period amounted to TSEK 57,069 (1,273) SIGNIFICANT EVENTS DURING THE FIRST QUARTER · Test material from upscaling to large-scale production of silica approved · Scientific advisory board within inhalation formed ·

Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova

Stockholm, Sweden, 23 April 2021 – Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch.Emollivet develops animal care products based on Lipidor's patented AKVANO technology. The company was funded in 2020 to focus on commercializing animal care products. Since Stina Linge was recruited as CEO last autumn, development in Emollivet has accelerated.

Success for trampolines with well-balanced Swedish quality springs

It´s springtime = time to jump around! With a new outdoor season just around the corner, the timing for a story about trampoline springs could not be better. Lesjöfors customized tension springs for trampolines have contributed to making North Trampoline's Performer a success.The introduction of the premium trampoline Performer has been a success for the Gothenburg-based trampoline specialist North Trampoline. The company ships trampolines to 22 countries in Europe and has just started sales in the US. Australia will follow later this year. North Trampoline expects that sales of the

Exel Composites Plc publishes its Q1 2021 Business Review on 30 April 2021

EXEL COMPOSITES PLC      INVESTOR NEWS      23 APRIL 2021 at 09:00 EETExel Composites Plc publishes its Q1 2021 Business Review on Friday 30 April 2021 at approximately 9:00 EET. A financial results briefing for investors, analysts and journalists will be held the same day at 12:30 EET. The briefing will be hosted by Riku Kytömäki, President and CEO. The briefing will be organized online. Participants are requested to register to the event in advance by sending an email to investor@exelcomposites.com no later than by Wednesday 28 April 2021 at 16:00 EET. A link to join the event will be

Bluestep Bank’s Annual General Meeting 2021 and Annual and Sustainability report 2020

Bluestep Bank AB (publ)’s Annual General Meeting (AGM) was concluded on the 22nd of April 2021. The AGM decided to re-elect the Board of Directors and auditor. The Board of Directors and the Chief Executive Officer also present the Annual report of Bluestep Bank AB (publ) for 2020.Among other things, the AGM resolved the following: · The AGM approved the accounts for Bluestep Bank as well as the consolidated income statement and balance sheet. · The AGM approved that the appropriation of profits should be carried forward, in accordance with the Board’s proposal. · The Board and

Cloetta AB interim report Q1: January – March 2021

Strong quarter for Branded packaged products while Pick & mix was still negatively impacted by Covid-19, despite stronger Easter sales.· Net sales for the quarter decreased by 7.9 per cent to SEK 1,398m (1,518), including a negative impact from foreign exchange rates of 3.7 per cent. · Sales of Branded packaged products increased organically by 2.5 per cent during the quarter: 2.7 per cent in January, –0.1 per cent in February and 3.8 per cent in March. · Sales of Pick & mix declined organically by 22.9 per cent during the quarter: –38.5 per cent in January, –38.1 per cent in February

Paulig’s Annual Report 2020: Towards a sustainable future for food with a new sustainability approach

In its first year of implementation, Paulig's ambitious sustainability approach has already yielded concrete results. In 2020, Paulig reduced greenhouse gas (GHG) emissions from its own operations by 18%. In addition, the company’s Vuosaari roastery in Finland became its first certified CarbonNeutral® production site. Paulig also tested new, more environmentally friendly packaging materials and introduced carbon-neutral pallets. Paulig has published its Annual Report along with its Sustainability Report for 2020 

Cloetta refinances the Group through its existing banks for up to four years

Cloetta continues the financing through its existing banking group by entering into a new multicurrency term and revolving facilities agreement. Cloetta furthermore resolved to continue its existing commercial paper program.The terms as agreed in the facilities agreement will come into effect on 30 June 2021 and comprise, in short, of: · a SEK 800m term loan repayable on 30 June 2023, with the possibility of extending the facility for an additional two years; · a EUR 125m term loan repayable on 30 June 2024, with the possibility of extending the facility for an additional two years;

Annual report for year 2020

  Speqta AB’s annual report for 2020 is now published and available on https://speqta.com/en/investors/financial-reportsContactFredrik LindrosCEO Speqta AB (plc)fredrik.lindros@speqta.com+46 723 10 66 66About SpeqtaSpeqtas offers the best performance-based leads generating platforms, using data and AI and shall grow both organically and through acquisitions, in new and existing markets. The company has two business areas, Speqta AdTech and Speqta Content & Comparison. The company is listed on Nasdaq First North Premier Growth Market, in Stockholm under the name “

Relais Group Plc: Increases in the number of shares registered in the trade register

Relais Group Plc, Company Release 23 April 2021 at 9.00 a.m. EET Total of 430,559 share subscription based on the directed share issue approved by the Board of Directors of Relais Group Plc on 31 March 2021, have been entered into the trade register today. The subscription price for the shares was EUR 16.8131 per share. The directed issue is related to the closing of the acquisition of Lumise Oy announced on 31 March 2021. With the closing of the acquisition, Relais Group Plc paid EUR 7.24 million of the purchase price by issuing a total of 430,559 new Relais Group Plc's shares to be

Polygiene AB (publ) publish Annual Report for 2020

The Annual Report 2020 for Polygiene AB (publ) is now available at the company’s site https://ir.polygiene.com/en/ . The annual shareholders’ meeting to be held on Wednesday 19 May 2021. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the board of directors has decided that the annual shareholders’ meeting will be held only by advance voting (postal vote) in accordance with temporary legislation. This means that the annual shareholders’ meeting will be conducted

Q1 2021: Good growth in the first quarter

Significant events during the first quarter · Net sales increased by 9% (20% adjusted for currency changes) to SEK 171 m (158). · EBITDA margin was 28% (19%). · First deliveries related to the Pan-European agreement with Perrigo, which includes the launch of Probi's ClinBac™ concept in 14 European countries. · Strategic partnership with the Chinese pharmaceutical company China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade) a wholly owned subsidiary of China National Pharmaceutical Group Corporation (Sinopharm) for the launch of three of Probi's

REPORT ON THE FIRST QUARTER 2021

RECORD START TO THE YEAR FIRST QUARTER 2021 · Net sales were SEK 4,858 m (4,199); an increase of 16%. Organic growth was 22%. · Operating profit before depreciation and amortization (EBITDA) was SEK 917 m (597), representing a margin of 18.9% (14.2%). · Operating profit (EBIT) before items affecting comparability was SEK 731 m (421), representing a margin of 15.0% (10.0%). · Items affecting comparability were SEK -5 m (-32). · Operating profit (EBIT) was SEK 725 m (389), representing a margin of 14.9% (9.3%). · Profit for the period was SEK 490 m (204). · Earnings

There are no items matching the current filter
There are no more items matching the current filter
Back to top